204 related articles for article (PubMed ID: 23936189)
21. Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody.
Bignotti E; Ravaggi A; Romani C; Falchetti M; Lonardi S; Facchetti F; Pecorelli S; Varughese J; Cocco E; Bellone S; Schwartz PE; Rutherford TJ; Santin AD
Int J Gynecol Cancer; 2011 Dec; 21(9):1613-21. PubMed ID: 21892093
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
El-Sahwi K; Bellone S; Cocco E; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Mol Cancer Ther; 2010 Jan; 9(1):57-66. PubMed ID: 20053761
[TBL] [Abstract][Full Text] [Related]
23. The Ig V
Girola N; Matsuo AL; Figueiredo CR; Massaoka MH; Farias CF; Arruda DC; Azevedo RA; Monteiro HP; Resende-Lara PT; Cunha RL; Polonelli L; Travassos LR
Peptides; 2016 Nov; 85():1-15. PubMed ID: 27575453
[TBL] [Abstract][Full Text] [Related]
24. Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells.
Song JX; Cao WL; Li FQ; Shi LN; Jia X
Med Oncol; 2012 Dec; 29(4):2923-31. PubMed ID: 22198696
[TBL] [Abstract][Full Text] [Related]
25. Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314.
Kircheis R; Halanek N; Koller I; Jost W; Schuster M; Gorr G; Hajszan K; Nechansky A
MAbs; 2012; 4(4):532-41. PubMed ID: 22665069
[TBL] [Abstract][Full Text] [Related]
26. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
Cooley S; Burns LJ; Repka T; Miller JS
Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
[TBL] [Abstract][Full Text] [Related]
27. Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions.
Miller ML; Finn OJ
Methods Enzymol; 2020; 632():431-456. PubMed ID: 32000909
[TBL] [Abstract][Full Text] [Related]
28. Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity.
Kinouchi T; Bander NH; Kotake T
J Urol; 1995 Jul; 154(1):288-92. PubMed ID: 7776448
[TBL] [Abstract][Full Text] [Related]
29. Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models.
Patel SP; Bristol A; Saric O; Wang XP; Dubeykovskiy A; Arlen PM; Morse MA
Cancer Immunol Immunother; 2013 Jun; 62(6):1011-9. PubMed ID: 23591984
[TBL] [Abstract][Full Text] [Related]
30. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.
Ebel W; Routhier EL; Foley B; Jacob S; McDonough JM; Patel RK; Turchin HA; Chao Q; Kline JB; Old LJ; Phillips MD; Nicolaides NC; Sass PM; Grasso L
Cancer Immun; 2007 Mar; 7():6. PubMed ID: 17346028
[TBL] [Abstract][Full Text] [Related]
31. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
Klitgaard JL; Koefoed K; Geisler C; Gadeberg OV; Frank DA; Petersen J; Jurlander J; Pedersen MW
Br J Haematol; 2013 Oct; 163(2):182-93. PubMed ID: 23927424
[TBL] [Abstract][Full Text] [Related]
32. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
Richter CE; Cocco E; Bellone S; Silasi DA; Rüttinger D; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2010 Dec; 203(6):582.e1-7. PubMed ID: 20870202
[TBL] [Abstract][Full Text] [Related]
33. Sym015: A Highly Efficacious Antibody Mixture against
Poulsen TT; Grandal MM; Skartved NJØ; Hald R; Alifrangis L; Koefoed K; Lindsted T; Fröhlich C; Pollmann SE; Eriksen KW; Dahlman A; Jacobsen HJ; Bouquin T; Pedersen MW; Horak ID; Lantto J; Kragh M
Clin Cancer Res; 2017 Oct; 23(19):5923-5935. PubMed ID: 28679766
[No Abstract] [Full Text] [Related]
34. Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case study.
Dorvignit D; Palacios JL; Merino M; Hernández T; Sosa K; Casaco A; López-Requena A; Mateo de Acosta C
MAbs; 2012; 4(4):488-96. PubMed ID: 22647435
[TBL] [Abstract][Full Text] [Related]
35. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
Kaneko MK; Abe S; Ogasawara S; Fujii Y; Yamada S; Murata T; Uchida H; Tahara H; Nishioka Y; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
[TBL] [Abstract][Full Text] [Related]
36. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Arrojo R; Liu D; Rossi EA; Chang CH; Goldenberg DM
Bioconjug Chem; 2015 May; 26(5):919-31. PubMed ID: 25915780
[TBL] [Abstract][Full Text] [Related]
37. Methods to measure the binding of therapeutic monoclonal antibodies to the human Fc receptor FcγRIII (CD16) using real time kinetic analysis and flow cytometry.
Harrison A; Liu Z; Makweche S; Maskell K; Qi H; Hale G
J Pharm Biomed Anal; 2012 Apr; 63():23-8. PubMed ID: 22366323
[TBL] [Abstract][Full Text] [Related]
38. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.
Woodhouse CS; Morgan AC
Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860
[TBL] [Abstract][Full Text] [Related]
39. Antitumor activity of an anti-CD98 antibody.
Hayes GM; Chinn L; Cantor JM; Cairns B; Levashova Z; Tran H; Velilla T; Duey D; Lippincott J; Zachwieja J; Ginsberg MH; H van der Horst E
Int J Cancer; 2015 Aug; 137(3):710-20. PubMed ID: 25556716
[TBL] [Abstract][Full Text] [Related]
40. Phage display generation of a novel human anti-CD1A monoclonal antibody with potent cytolytic activity.
Bechan GI; Lee DW; Zajonc DM; Heckel D; Xian R; Throsby M; van Meijer M; Germeraad WT; Kruisbeek AM; Egeler RM; Arceci RJ
Br J Haematol; 2012 Nov; 159(3):299-310. PubMed ID: 22934889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]